Nivolumab and Ipilimumab for Metastat... - Advanced Prostate...

Advanced Prostate Cancer

22,277 members27,978 posts

Nivolumab and Ipilimumab for Metastatic Prostate Cancer with an Immunogenic Signature: Phase 2 Trial

God_Loves_Me profile image
0 Replies

(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between May 31 and June 4 was host to the Rapid Oral Abstract Session: Genitourinary Cancer - Prostate, Testicular, and Penile. Dr. Mark Linch presented results from the NEPTUNES (NCT03061539), a multi-centre two-cohort, biomarker-selected phase 2 trial evaluating Nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) for metastatic prostate cancer with an immunogenic signature.

Dr. Linch initiated his presentation by addressing the limited responses observed with immune checkpoint inhibitor monotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC) (1). This phenomenon is largely attributed to the prevalence of a "cold" tumor immune microenvironment. Anti-CTLA4 therapy has been found to induce T-cell infiltration in prostate cancer, but most importantly, the combination of anti-CTLA4 and anti-PD1 has demonstrated a signal of activity in unselected patients with mCRPC in the preliminary analysis of the CheckMate 650 Trial combining Nivolumab+ipilimumab (2). Moreover, up to 20% of patients with high-risk PCa have high tumor infiltrating lymphocytes (TILs), which have been shown, albeit inconsistently, to be prognostic in PCa. (3)

urotoday.com/conference-hig...

Written by
God_Loves_Me profile image
God_Loves_Me
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Olaparib for Metastatic Castration-Resistant Prostate Cancer

TAKE-HOME MESSAGE •In this phase III study, 387 patients with metastatic castration-resistant...
Balsam01 profile image

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer

TAKE-HOME MESSAGE •The authors report on 3 cohorts of patients with metastatic...
Balsam01 profile image

Nivolumab plus ipilimumab.

Presented at the Genitourinary Cancers Symposium in San Francisco, which ends today. [1] “This was...
pjoshea13 profile image

FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

Other triple therapy approved by the FDA. The article has the basic results of the ARASENS trial....
tango65 profile image

Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

FORT LAUDERDALE, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage...
God_Loves_Me profile image